Brii Biosciences and Joincare Group Forge Strategic Licensing Deal for BRII-693 in Greater China Market

Brii Biosciences Partners with Joincare for BRII-693



In a significant step towards addressing the rising threat of antimicrobial resistance, Brii Biosciences Limited, a biotechnology firm dedicated to elevating patient health through innovative therapies, announced a licensing and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd. This new partnership allows Joincare Group exclusive rights to conduct research, development, and commercialization of the acute care antibiotic, BRII-693, across the Greater China region.

Licensing Agreement Overview


The agreement, effective from July 3, 2025, puts Joincare Group in the driver’s seat for the development and regulatory approval of BRII-693, a critical treatment option for patients suffering from multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant pathogens like Acinetobacter baumannii and Pseudomonas aeruginosa. As part of this arrangement, Brii Bio will receive an upfront payment along with milestone-based payments and tiered royalties on net sales of the product.

Joincare Group’s extensive expertise in the pharmaceutical sector positions them well for this undertaking, particularly as they have shown a strong track record in developing and launching hospital antibiotics effectively. Dr. Zhi Hong, Chairman and CEO of Brii Bio, emphasized the urgency of combating antimicrobial resistance in the region. He remarked, “The increasing threat of antimicrobial resistance in Greater China highlights the need for innovative hospital antibiotics. With Joincare Group, we found an appropriate partner to expedite the development and supply of BRII-693 to patients facing severe infections.”

What is BRII-693?


BRII-693 is a synthetic lipopeptide that is currently undergoing clinical trials aimed at treating critically ill patients impacted by resistant bacterial strains. The compound has been engineered through advanced structural modifications on the polymyxin scaffold, designed to increase its antibacterial effects while minimizing the risk of toxicity—a common issue with older antibiotics. Initial phase 1 trials have achieved promising results regarding safety and tolerability in both non-Chinese and Chinese participants.

The drug has received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China, thereby paving the way for a phase 1 pharmacokinetic bridging study and a future phase 3 trial targeting patients diagnosed with hospital-acquired pneumonia and ventilator-associated pneumonia—serious medical conditions that often arise in healthcare settings.

The Future of BRII-693


Looking ahead, Mr. Nanqi Lin, CEO of Joincare Group, expressed confidence in the potential of BRII-693, noting that the collaboration would enhance their strategic presence in the anti-infection sector. “Our combination of scientific expertise and innovative drug development aligns with Brii Bio’s established systems ensuring a strong pipeline and potential for BRII-693 to emerge as a leading therapy,” he stated.

With both companies investing in this promising treatment, BRII-693 stands on the brink of addressing critical unmet clinical needs in the realm of antibacterial therapies, particularly in managing infections that have not responded to conventional treatments.

About Brii Biosciences


Brii Biosciences Limited operates as a biotechnology innovator focusing on serious public health issues, with particular emphasis on infectious diseases. The corporation aims to alleviate significant social stigmas and enhance treatment options in areas of high unmet medical needs. Its primary programs target diseases such as hepatitis B, among others, and the company operates globally with key locations in biotech hubs like Raleigh-Durham and Beijing.

About Joincare Group


Founded in 1992, Joincare Group has evolved into an integrated pharmaceutical powerhouse, bolstered by a commitment to scientific innovation. With significant investments in diverse therapeutic areas such as oncology and anti-infectives, Joincare has established a strong presence in drug discovery and development that complements the strategic focus of BRII-693.

The partnership between Brii Biosciences and Joincare is set to propel advancements in antibiotic therapies, contributing significantly to public health in Greater China amidst rising rates of antimicrobial resistance.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.